neuropsychiatry | CARLAT PUBLISHING

CARLAT WEBINAR

How to Select a Stimulant Formulation

December 6, 2022

Chris Aiken, MD

Which isomer mix should you choose, and which release mechanism is the best fit for your patient?

Interpreting Assessment Discrepancies from Multiple Sources

October 17, 2022

Joshua Feder, MD and Mara Goverman

In this episode, we will discuss why assessment discrepancies arise, how we can manage them, and what these discrepancies tell us about a patient’s symptoms and response to treatment.

Amphetamine vs Methylphenidate

October 5, 2022

Chris Aiken, MD

Clinicians should understand how amphetamine and methylphenidate differ in respect to their: risks of psychosis, mania, and substance use, neurotoxic and neuroprotective properties, efficacy and tolerability, and use across the lifespan.

EXPERT Q&A

Assessing and Treating Catatonia in Children and Adolescents

October 1, 2022

Lee Wachtel MD

Lee Wachtel, MD, Medical Director, Neurobehavioral Unit, Kennedy Krieger Institute. Psychiatry Professor, Johns Hopkins School of Medicine. Baltimore, MD.

Dr. Wachtel, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Catatonia is marked by a change from the person’s baseline state with distinct motor, vocal, and behavioral symptoms. Clinicians usually think of a catatonic person as being like a statue—immobile, unresponsive, staring, and with waxy flexibility.

RESEARCH UPDATE

Do White Matter Hyperintensities Predict Memory Loss with Electroconvulsive Therapy?

October 1, 2022

Dax Volle, MD

Dax Volle, MD. Dr. Volle, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

We can continue to recommend ECT to patients with severe white matter hyperintensities and cognitive impairment, as cognition seems to return to baseline following ECT.

CLINICAL UPDATE

A Diet for ADHD

September 25, 2022

Chris Aiken, MD and Uma Naidoo, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Uma Naidoo, MD. Director of Nutritional and Metabolic Psychiatry, Massachusetts General Hospital (MGH); Director of Nutritional & Lifestyle Psychiatry, MGH Academy; Author, This Is Your Brain on Food (Little, Brown Spark; 2020).

The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

After years of suggestive studies, the first randomized controlled to test a practical approach to diet in ADHD is out. Find out which foods to eat, and which to avoid.

Structural Brain Changes After ECT for Depression

April 5, 2022

Chris Aiken, MD and Batya Swift Yasgur, MA, LSW

Chris Aiken, MD Batya Swift Yasgur, MA, LSW The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How does ECT change the brain? A systemic review offers up some answers.

EXPERT Q&A

Neurobiology Concepts for Psychiatrists

June 1, 2018

David M. Kaufman, MD

David M. Kaufman, MD Department of Neurology, Montefiore Medical Center, Bronx, NY. Co-author of Kaufman’s Clinical Neurology for Psychiatrists, 8th ed. (Elsevier). Dr. Kaufman has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The most common cause of parkinsonism is Parkinson disease, but parkinsonism also can occur from the use of any medication that blocks the D2 (dopamine type 2) receptor. Those include antipsychotics but can also include non-psychiatric medicines, particularly metoclopramide (Reglan), an anti-nausea medicine.

Assessing and Treating Psychogenic Pain

May 1, 2018

Howard Schubiner, MD

Howard Schubiner, MD Director of the Mind Body Medicine Program at Providence Hospital, Southfield, MI. Coauthor of the book Unlearn Your Pain: A 28-Day Process to Reprogram Your Brain. Dr. Schubiner has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

All pain is real. It’s just a question of whether that pain is being triggered by a physical injury or by something else. Studies show that emotional injury activates the same areas of the brain as does physical injury.

EXPERT Q&A

The Neurobiology of Schizophrenia

March 1, 2009

Fredrik Jarskog, MD

Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?